Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2026
Subject: Advancement of mRNA seasonal flu vaccine candidate to Phase III following positive Phase II data.
Key Financial Metrics
This filing is a corporate announcement regarding clinical trial progress and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Progress
- Phase II Results: GSK's mRNA flu vaccine candidate demonstrated higher immune responses against all tested influenza strains compared to licensed standard dose and high dose inactivated flu vaccines in younger (18-64) and older (≥65) adults.
- Safety Profile: The vaccine was generally well tolerated with acceptable reactogenicity and safety profiles.
- Next Steps: GSK intends to initiate a Phase III efficacy trial in September 2026.
- Regulatory Status: In July 2026, the US FDA granted Fast Track designation for the vaccine candidate for the targeted age indication.
Outlook, Management Commentary, and Risks
Management Commentary: Sanjay Gurunathan, Head of Vaccines and Infectious Diseases R&D, stated that the data supports the potential for better protection by targeting both haemagglutinin (HA) and neuraminidase (NA). He highlighted the global need for next-generation vaccines given one billion annual flu cases and up to 650,000 deaths.
Outlook: The Phase III trial will be the first of its kind to target both HA and NA antigens, aiming to improve protection, illness severity, and transmission reduction.
Risks and Contingencies: The filing includes a cautionary statement that forward-looking statements are subject to risks and uncertainties. Actual results may differ materially from projections due to factors described in GSK's 2025 Form 20-F and Q2 2026 results. The vaccine candidate is not currently approved anywhere in the world.
Investor Verification Checklist
- Verify the specific design and endpoints of the upcoming Phase III efficacy trial starting September 2026.
- Confirm the timeline for Phase III data readout and potential regulatory submission dates.
- Review the "Risk Factors" section in the 2025 Form 20-F and Q2 2026 results for detailed clinical and commercial risks.
- Monitor FDA communications regarding the Fast Track designation and any potential changes in regulatory requirements.